Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.44 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.44 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.44 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1257312 | 0.95 | RAB9A (0.50) | NCOA1NCOA3DYRK1ACLK4GAA | |
| SCHEMBL9377137 | 0.87 | DYRK1A (0.50) | NCOA1NCOA3DYRK1ACLK4GAA | |
| SCHEMBL19288648 | 0.82 | HRH2 (0.40) | NCOA1NCOA3DYRK1ACLK4GAA | |
| SCHEMBL31240857 | 0.82 | PDGFRB (0.46) | RAB9ANPC1CYP1A1CYP1A2CYP2E1 | |
| SCHEMBL1630255 | 0.81 | NPC1 (0.57) | RAB9ANPC1CYP1A2CYP3A4CYP2A6 | |
| SCHEMBL14704908 | 0.81 | CD274 (0.46) | NCOA1NCOA3DYRK1ACLK4GAA | |
| SCHEMBL14704745 | 0.80 | QDPR (0.51) | NCOA1NCOA3GAACYP1A2CYP3A4 | |
| SCHEMBL8939884 | 0.80 | KCNH2 (0.47) | CLK4RAB9ANPC1CA1CA2 | |
| SCHEMBL2572521 | 0.79 | PRMT5 (0.46) | PDGFRBPDGFRA | |
| SCHEMBL16566323 | 0.79 | CYP1A2 (0.49) | CYP1A2CYP2C9CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1420771-B9 | USE OF TRIFLUOROACETYL ALKYL-SUBSTITUTED PHENYL DERIVATIVES, PHENOL DERIVATIVES, AND BENZOYL DERIVATIVES IN THE TREATMENT AND/OR PROPHYLAXIS OF OBESITY AND ACCOMPANYING DISEASES AND/OR SECONDARY DISEASES | SOLVAY PHARM GMBH (DE) | 2007-10-17 | — | — | EP | disclosed |
| EP-1420771-B1 | USE OF TRIFLUOROACETYL ALKYL-SUBSTITUTED PHENYL DERIVATIVES, PHENOL DERIVATIVES, AND BENZOYL DERIVATIVES IN THE TREATMENT AND/OR PROPHYLAXIS OF OBESITY AND ACCOMPANYING DISEASES AND/OR SECONDARY DISEASES | SOLVAY PHARM GMBH (DE) | 2006-09-06 | — | — | EP | disclosed |
| US-6930207-B2 | Trifluoroacetylalkyl-substituted phenyl, phenol and benzoyl compounds and related methods of treatment | SOLVAY PHARMACEUTICAL GMBH (DE) | 2005-08-16 | — | — | US | disclosed |
| US-20040214901-A1 | Trifluoroacetylalkyl-substituted phenyl, phenol and benzoyl compounds and related methods of treatment | SOLVAY PHARMACEUTICALS GMBH (DE) | 2004-10-28 | — | — | US | disclosed |
| EP-1420771-A2 | USE OF TRIFLUOROACETYL ALKYL-SUBSTITUTED PHENYL DERIVATIVES, PHENOL DERIVATIVES, AND BENZOYL DERIVATIVES IN THE TREATMENT AND/OR PROPHYLAXIS OF OBESITY AND ACCOMPANYING DISEASES AND/OR SECONDARY DISEASES | Solvay Pharmaceuticals GmbH (DE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003007923-A2 | USE OF TRIFLUOROACETYL ALKYL-SUBSTITUTED PHENYL DERIVATIVES, PHENOL DERIVATIVES, AND BENZOYL DERIVATIVES IN THE TREATMENT AND/OR PROPHYLAXIS OF OBESITY AND ACCOMPANYING DISEASES AND/OR SECONDARY DISEASES | SOLVAY PHARMACEUTICALS GMBH (DE) | 2003-01-30 | — | — | WO | disclosed |
| US-4291059-A | 1-PHENYLCYCLOPENTANOL ACYLATE ESTER AND ITS PREPARATION | GLAXO GROUP LIMITED (GB) | 1981-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214901-A1 | Trifluoroacetylalkyl-substituted phenyl, phenol and benzoyl compounds and related methods of treatment | PNLIP, LIPC, CEL | NCOA1 105/4885NCOA3 119/4885DYRK1A 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.